MyChem Sells To Maravai LifeSciences
BroadOak Partners advises MyChem, LLC on the sale of the company to Maravai LIfeSciences (NASDAQ: MRVI). MyChem is a leading provider of proprietary, ultra-pure nucleotides to customers in the diagnostics, pharma, genomics, and research markets. The full press release is below. MyChem’s nucleotide synthesis methods are highly complementary to Maravai’s TriLink mRNA technologies Increases capabilities […]
JMI Announces Sale to Element Materials Technology
BroadOak Capital Partners advised JMI Laboratories (“JMI”) on the sale of the company to Element Materials Technology (“Element”). JMI is a leading provider of antimicrobial drug development, molecular testing, clinical trial support, and surveillance services to biotech and pharmaceutical companies. The full press release is below. Element strengthens pharmaceutical and biotech capability with JMI Laboratories […]
Nanosyn Sells to Element Materials Technology
BroadOak Partners advises Nanosyn on the sale of the company to Element Materials Technology (“Element”). Nanoysn is a full-service drug discovery CDMO that provides chemistry, biology, API, and formulation services to pharmaceutical companies. The full press release is below. Element further bolsters its pharmaceuticals offering with Nanosyn acquisition London, UK – October 11, 2021 – […]
KCAS Sells To Vitruvian
BroadOak Capital Partners advised KCAS Bioanalytical and Biomarker Services (“KCAS”) on the sale of the company to Vitruvian. KCAS is a leading contract research organization providing comprehensive GLP-compliant bioanalytical and biomarker development testing services for the biotech, pharmaceutical, and animal health industries. The full press release is below. Vitruvian Partners announces strategic growth investment in […]
Cenetron Sells To Versiti
BroadOak Partners advised Cenetron Diagnostics (“Cenetron”) on the sale of the company to Versiti. Cenetron provides central laboratory services to support global clinical trials for biopharmaceutical, diagnostic, and contract research organizations. The full press release is below. Versiti Acquires Texas-based Cenetron Central Laboratories and Salus IRB to Advance Clinical Trial Capabilities Milwaukee, Wis., – July […]
Astero Bio Sells To BioLife Solutions
BroadOak Capital Partners advised Astero Bio Corporation (“Astero”) on the sale of the company to BioLife Solutions. Astero is a provider of innovative tools that improve the quality of high-value cell and gene therapies. The full press release is below. BioLife Solutions Expands Cell and Gene Therapy Tools Portfolio with Acquisition of Astero Bio Gains […]
DANI Instruments Sells To PerkinElmer
BroadOak Partners advises DANI Instruments (“DANI”) on its sale to PerkinElmer. DANI is a provider of advanced gas chromatography instruments and systems for food analysis, pharmaceutical, and environmental applications. The full story is below. PerkinElmer Revenues Grow 22 Percent, Diagnostics Up 59 Percent NEW YORK (GenomeWeb) – PerkinElmer said after the close of the market […]
LifeSpan Biosciences Sells To Thompson Street
BroadOak Partners advises LifeSpan Biosciences (“LSBio”) on the sale of the company to Thompson Street Capital Partners. LSBio provides antibodies and life science reagents to the academic and pharmaceutical research markets through its proprietary e-commerce platform. The full press release is below. Thompson Street Capital Partners Acquires LifeSpan Biosciences, Inc. ST. LOUIS–(BUSINESS WIRE)–Thompson Street Capital […]
Lucigen Sells To LGC
BroadOak Partners advises Lucigen Corporation on the sale of the company to LGC Limited. Lucigen is a leading provider of molecular biology enzymes, reagents, and kits for high growth applications in clinical diagnostics, drug discovery, synthetic biology, and gene editing. The full press release is below. LGC acquires Lucigen, strengthening its reagents offering to the […]